Follows adults with chronic hepatitis B whose hepatitis B surface antigen levels dropped
Follows adults with chronic hepatitis B to see how treatment affects antigen loss.
Plain-language title generated from the registry record
Registry title: HBsAg Declined Patients Follow-up Study
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05977283, who can take part
Where in China
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanfang Hospital, Southern Medical University
- Trial code
- NCT05977283
- Record updated
- 20 February 2024
- Original description
The goal of this observational study is to prospectively follow chronic hepatitis B patients who had HBsAg decline in the past 12 months prior to screening. The main question it aims to answer are:Read full original descriptionShow less
An Observational Follow-up Study to Describe Treatment Patterns and Outcomes in Hepatitis B Patients With HBsAg Decline in Past 6 Months
The goal of this observational study is to prospectively follow chronic hepatitis B patients who had HBsAg decline in the past 12 months prior to screening. The main question it aims to answer are:
- Describe treatment pattern and its impact on HBsAg loss in hepatitis B patients who had HBsAg decline in past 12 months due to any reason (with or without new molecular entities therapy).
Participants will be followed up for 36 months after enrollment and may be extended upon expiration according to study objectives.
Inclusion: Participants must have HBsAg decline ≥0.5 log10 IU/mL in past 12 months prior to screening due to any reason (with or without new molecular entities therapy). Among the enrolled subjects, 70% must have HBsAg decline ≥1 log10 IU/mL or actual values ≤3 log10 IU/mL; Able and willing to provide written informed consent and to comply with the study protocol according to International Council for Harmonization (ICH) and local regulations.
Exclusion: Any condition which, in the opinion of the investigator, contraindicates their participant in this study; Participants who are currently participating in interventional clinical study exploring HBV treatment.